WHO ICTRP trial
Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy…
EUCTR2009-011776-30-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-011776-30-DE |
|---|---|
| Public title | Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg plus Hydrochlorothiazide 25 mg in Patients with Severe Hypertension |
| Scientific title | Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg plus Hydrochlorothiazide 25 mg in Patients with Severe Hypertension |
| Primary sponsor | Takeda Pharma GmbH |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Germany |
| Conditions | Subjects with severe essential hypertension (SBP between 150 mmHg and 200 mmHg AND DBP between 110 mmHg and 120 mmHg) who did not receive any antihypertensive treatment before will be included in the study MedDRA version: 9.1 Level: LLT… |
| Interventions | Trade Name: Blopress 16 mg Tabletten Product Name: Candesartan Cilexetil 16 mg Pharmaceutical Form: Tablet INN or Proposed INN: CANDESARTAN CAS Number: 139481597 Current Sponsor code: CV 11974 Concentration unit: mg milligram(s)… |
| Registration date | Jul 13, 2009 |
| Target size | 100 |
| Secondary IDs | DE-CAN-027 (BLO K027) |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: